We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Ultra-High-Throughput PCR Testing System for SARS-CoV-2 Detection Can Test up to 150,000 Patient Samples per Day

By LabMedica International staff writers
Posted on 16 Sep 2021
Illustration
Illustration
A new ultra-high-throughput PCR testing system for SARS-CoV-2 detection can test up to 150,000 patient samples per day.

The proven molecular genomics testing platform with unmatched capacity that has been developed by LGC, Biosearch Technologies (Hertfordshire, UK) is expected to redefine large-scale COVID-19 testing. For labs ready to scale to support mass testing, the company is offering the ultra-high-throughput (uHTP) end-point PCR testing system for SARS-CoV-2 detection.

The Biosearch Technologies workflow combines the Nexar industrial scale, automated end-point PCR testing platform with our robust, high-quality testing reagent components. UgenTec’s FastFinder software seamlessly integrates with the company’s instrumentation to provide full traceability of the sample down to individual wells on the Array Tape consumable, which allows the user to easily pull up a sample’s status. Biosearch Technologies’ SARS-CoV-2 testing workflow can expand testing capacity to as many as 150,000 samples per day with minimal need for additional staff, instrumentation, or lab space.

Biosearch Technologies' SARS-CoV-2 testing system is good for screening symptomatic and asymptomatic individuals. It is compatible with anterior nares specimens self-collected in a non-medical setting or by a healthcare professional within a healthcare setting. The system features an easy dry swab collection device that is safe for handling, better for shipping, and automation-friendly. Biosearch Technologies’ SARS-CoV-2 testing workflow features an extraction-free process without compromising sensitivity of a 250 cp/swab limit of detection (LoD).

Related Links:
LGC, Biosearch Technologies

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gel Cards
DG Gel Cards

Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
GLOBE SCIENTIFIC, LLC